New England Business and Technology Association to Host ''The New Biotech/Pharma Research Organization'' As Part of Association's Pipeline Series.
BOSTON Boston, town, England
Boston, town (1991 pop. 26,495), E central England, on the Witham River. Boston's fame as a port dates from the 13th cent., when it was a Hanseatic port trading wool and wine. Having recovered from a decline in the 18th and 19th cent. -- Participants include Brock brock
n. Chiefly British
[Middle English brok, from Old English broc, of Celtic origin.] Reeve REEVE. The name of an ancient English officer of justice, inferior in rank to an alderman.
2. He was a ministerial officer, appointed to execute process, keep the king's peace, and put the laws in execution. of Life Sciences Insights, Rainer The name Rainer comes from the Germanic name Reginar, composed of the two elements ragin ("advice") and heri ("army"). The name was brought to Britain by the Normans. Fuchs Fuchs , Klaus Emil Julius 1911-1988.
German-born physicist who worked on the development of the atomic bomb in Britain and the United States and was imprisoned (1950-1959) for passing scientific secrets to the Soviet Union.
Noun 1. , PhD of Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec , and Ellen Ridge of Genzyme Corporation
WHAT: The New England Business and Technology Association (NEBATA) announces that it will host an interactive panel discussion entitled "The New Biotech/Pharma Research Organization" as part of the Association's Pipeline Series. The session will be held on Tuesday, November 9, 2004 at Wilmer Cutler Pickering Hale and Dorr, LLP, 60 State Street, Boston, MA. "The New Biotech/Pharma Research Organization" will focus on addressing key issues and questions that arise for biotechnology and pharmaceutical companies such as: -- What is the "future state" of research and discovery? What will winning companies do differently in one, three, five and ten years? -- What is driving companies toward that "future state?" How can the great goal of "getting more for less" be a realized? How will companies be able to get more drugs approved per each investment dollar? -- What will winning companies do from a technology point of view to reach this end point faster and more efficiently? How will companies be able to get "spend" aligned with company strategies and goals? WHO: Confirmed participants include: Brock Reeve, Vice President, Consulting Practice - Life Science Insights (moderator) Rainer Fuchs PhD, Vice President, Research Informatics - Biogen Idec, Inc. Andy Palmer, CIO & Senior Vice President, Operations - Infinity Pharmaceuticals Ellen Ridge, Vice President - Genzyme Corporation David Yee, Head of Knowledge and Information Systems - Archemix WHEN: Tuesday, November 9, 2004 7:30 a.m. - Registration 8:00 a.m. - Panel 10:00 a.m. - Networking Reception WHERE: Wilmer Cutler Pickering Hale and Dorr, LLP 60 State Street, Boston, MA
To register for this event, please send contact information to firstname.lastname@example.org. Cost for members is $40; non-members, $80. To receive a press pass, please contact Shannon Altimari at 617-520-7250 or email@example.com.
The NEBATA Pipeline Series is made possible through sponsorship by Wilmer Cutler Pickering Hale and Dorr Wilmer Cutler Pickering Hale and Dorr LLP, which also goes by the shorter market name WilmerHale, is a leading American law firm with major offices in Washington, Boston and New York and smaller offices in Palo Alto, Baltimore, London, Brussels, Beijing, Berlin, Los , LLP LLP - Lower Layer Protocol , Computer Associates and New Tilt.